Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metoprolol + telmisartan
- Development stage
- Unknown
- Lead developer
- Medley
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telmed Beta is a fixed-dose combination antihypertensive medication developed by Medley. It contains metoprolol succinate, a cardioselective beta-1 adrenergic receptor blocker, and telmisartan, an angiotensin II receptor blocker (ARB). Metoprolol works by reducing heart rate, cardiac output, and myocardial oxygen demand, while telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to arterial vasodilation and reduced peripheral resistance. Together, these complementary mechanisms provide synergistic blood pressure control. Telmed Beta is approved for the treatment of hypertension, particularly in patients whose blood pressure is uncontrolled on monotherapy, as well as hypertension co-occurring with heart failure or coronary artery disease.
- Brand names
- Macsart BetaMetosartanNewtel BetaTAZloC-BetaTelma-BetaTelmaxxTelmed BetaTelmikind BetaTelmital BetaTelsar BetaTelvas BetaXstan-beta
- Other names
- metoprolol succinate + telmisartantelmisartan + metoprololtelmisartan + metoprolol succinatetelmisartan and metoprololtelmisartan and metoprolol succinate
02
Targets
ADRB1 (β1)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on metoprolol + telmisartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metoprolol + telmisartan.